143 related articles for article (PubMed ID: 8260894)
1. L-myc and N-myc in hematopoietic malignancies.
Hirvonen H; Hukkanen V; Salmi TT; Pelliniemi TT; Alitalo R
Leuk Lymphoma; 1993 Oct; 11(3-4):197-205. PubMed ID: 8260894
[TBL] [Abstract][Full Text] [Related]
2. Expression of L-myc and N-myc proto-oncogenes in human leukemias and leukemia cell lines.
Hirvonen H; Hukkanen V; Salmi TT; Mäkelä TP; Pelliniemi TT; Knuutila S; Alitalo R
Blood; 1991 Dec; 78(11):3012-20. PubMed ID: 1954386
[TBL] [Abstract][Full Text] [Related]
3. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
Liebermann DA; Hoffman B
Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
[TBL] [Abstract][Full Text] [Related]
4. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
[TBL] [Abstract][Full Text] [Related]
5. What retroviruses teach us about the involvement of c-Myc in leukemias and lymphomas.
Dudley JP; Mertz JA; Rajan L; Lozano M; Broussard DR
Leukemia; 2002 Jun; 16(6):1086-98. PubMed ID: 12040439
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of c-erbB, c-myc and c-myb oncogene loci in human lymphomas and leukemias.
Roy-Burman P; Devi BG; Parker JW
Int J Cancer; 1983 Aug; 32(2):185-91. PubMed ID: 6603429
[TBL] [Abstract][Full Text] [Related]
7. IgH enhancer-mediated deregulation of N-myc gene expression in transgenic mice: generation of lymphoid neoplasias that lack c-myc expression.
Dildrop R; Ma A; Zimmerman K; Hsu E; Tesfaye A; DePinho R; Alt FW
EMBO J; 1989 Apr; 8(4):1121-8. PubMed ID: 2501083
[TBL] [Abstract][Full Text] [Related]
8. Transformation of hemopoietic cells by raf and myc oncogenes: a new perspective on lineage commitment.
Klinken SP
Cancer Cells; 1991 Oct; 3(10):373-82. PubMed ID: 1777358
[TBL] [Abstract][Full Text] [Related]
9. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.
Sewastianik T; Prochorec-Sobieszek M; Chapuy B; Juszczyński P
Biochim Biophys Acta; 2014 Dec; 1846(2):457-67. PubMed ID: 25199984
[TBL] [Abstract][Full Text] [Related]
10. Deregulated c-myb disrupts interleukin-6- or leukemia inhibitory factor-induced myeloid differentiation prior to c-myc: role in leukemogenesis.
Selvakumaran M; Liebermann DA; Hoffman-Liebermann B
Mol Cell Biol; 1992 Jun; 12(6):2493-500. PubMed ID: 1588953
[TBL] [Abstract][Full Text] [Related]
11. MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation.
Schreiner S; Birke M; García-Cuéllar MP; Zilles O; Greil J; Slany RK
Cancer Res; 2001 Sep; 61(17):6480-6. PubMed ID: 11522644
[TBL] [Abstract][Full Text] [Related]
12. A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice.
Nussenzweig MC; Schmidt EV; Shaw AC; Sinn E; Campos-Torres J; Mathey-Prevot B; Pattengale PK; Leder P
Nature; 1988 Dec; 336(6198):446-50. PubMed ID: 3143076
[TBL] [Abstract][Full Text] [Related]
13. IgH enhancer deregulated expression of L-myc: abnormal T lymphocyte development and T cell lymphomagenesis.
Möröy T; Fisher P; Guidos C; Ma A; Zimmerman K; Tesfaye A; DePinho R; Weissman I; Alt FW
EMBO J; 1990 Nov; 9(11):3659-66. PubMed ID: 2120050
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNAs and MYC association in hematological malignancies.
Benetatos L; Benetatou A; Vartholomatos G
Ann Hematol; 2020 Oct; 99(10):2231-2242. PubMed ID: 32621182
[TBL] [Abstract][Full Text] [Related]
15. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
Strasser A; Harris AW; Bath ML; Cory S
Nature; 1990 Nov; 348(6299):331-3. PubMed ID: 2250704
[TBL] [Abstract][Full Text] [Related]
16. Uncoupling between Ig somatic hypermutation and oncogene mutation in mouse lymphoma.
Vincent C; Truffinet V; Fiancette R; Petit B; Cogné N; Cogné M; Denizot Y
Biochim Biophys Acta; 2009 Feb; 1793(2):418-26. PubMed ID: 19026697
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of the oncoproteins c-myc and c-myb in human lymphoproliferative disorders.
Siegert W; Beutler C; Langmach K; Keitel C; Schmidt CA
Eur J Cancer; 1990; 26(6):733-7. PubMed ID: 2144164
[TBL] [Abstract][Full Text] [Related]
18. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice.
Langdon WY; Harris AW; Cory S; Adams JM
Cell; 1986 Oct; 47(1):11-8. PubMed ID: 3093082
[TBL] [Abstract][Full Text] [Related]
19. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
20. [Activation of protooncogenes by point mutations in hematological malignancies].
Goto T; Nishimura J
Nihon Rinsho; 1992 Jun; 50(6):1335-40. PubMed ID: 1518154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
